On July 28, 2026, Viking Therapeutics Inc VKTX is poised to release its Q2 earnings report after market close, with analysts forecasting an EPS of -$1.21. This biotech company remains unprofitable and cash-flow negative, a dynamic that shapes how investors and the market value its shares.
- Market Cap: $3.82 billion, reflecting significant investor expectations despite ongoing losses
- GF Scoreâ„¢: 34/100, indicating weak overall financial health with notable momentum but poor profitability
- Guru 13F Activity: Four gurus currently hold VKTX, with a net trimming trend as four gurus trimmed positions versus two adding recently
What's Behind the News?
Viking Therapeutics is scheduled to report its second-quarter earnings on July 29, 2026, after the market closes. The consensus estimate points to a loss per share of $1.21, continuing a trend of negative earnings that has persisted for several years. Over the past three months, analyst EPS estimates have been volatile, with three upward revisions countered by eight downward adjustments, signaling uncertainty about the company’s near-term financial trajectory.
Viking Therapeutics operates in the biotechnology sector, focusing on developing therapies for metabolic and endocrine disorders. Its pipeline includes several clinical-stage drug candidates such as VK2809, VK5211, and VK0214, with a Phase III trial for VK2735 planned to commence in Q4 2026. The company’s market capitalization stands at $3.82 billion, underscoring investor interest in its long-term potential despite current financial challenges.
How Is VKTX Valued?
Due to the company’s persistent unprofitability and lack of meaningful revenue, traditional earnings-based valuation metrics like the price-to-earnings (P/E) ratio are not applicable for Viking Therapeutics. The trailing twelve months (TTM) EPS remains deeply negative at -$4.14, and the forward P/E ratio is not meaningful. Consequently, GF Value™ data is unavailable for VKTX, reflecting the difficulty in applying standard valuation models to a clinical-stage biotech firm with no sales.
Investors instead rely on alternative metrics such as price-to-book (P/B) ratio and market sentiment indicators. VKTX’s P/B ratio is elevated at 7.6, suggesting the market is pricing in significant future growth potential from its drug pipeline rather than current earnings. The stock has traded in a 52-week range between $22.96 and $43.15, with a recent price of approximately $32.89, indicating moderate volatility.
For more detailed valuation insights, visit the VKTX stock page.
What Does VKTX's GF Scoreâ„¢ Tell Us?
The GF Score™ aggregates multiple facets of a company’s financial health, including profitability, growth, financial strength, valuation, and momentum, to provide a comprehensive snapshot of its overall quality. Viking Therapeutics’ GF Score™ of 34 out of 100 reflects a company struggling with profitability and financial efficiency but showing some positive momentum.
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 34/100 |
| Financial Strength | 7/10 |
| Profitability | 1/10 |
| Momentum | 8/10 |
While the company’s financial strength is relatively solid, supported by a strong current ratio of 5.72 and no debt, its profitability is severely lacking, with a return on equity (ROE) of -67.55% and return on assets (ROA) of -62.84%. The high momentum ranking suggests recent positive price trends or market interest, possibly driven by pipeline developments or sector dynamics. However, the low profitability score signals ongoing operational challenges and cash burn.
Explore more on the GF Scoreâ„¢ and related metrics at the VKTX stock page.
What Are Gurus and Insiders Doing with VKTX?
GuruFocus tracks 143 premium gurus, and currently, four hold positions in Viking Therapeutics. However, recent activity shows a net reduction in guru ownership, with four gurus trimming their stakes while only two increased theirs in recent quarters. This mixed guru sentiment highlights cautious optimism but also some reservations among top investors regarding VKTX’s near-term prospects.
Insider activity over the past 12 months reveals seven insider sales totaling approximately $14.6 million, contrasted with a single insider purchase valued around $150,000. No insider buying or selling has been reported in the last three months. The relatively high insider selling combined with limited recent insider buying may reflect management’s view on valuation or liquidity needs but also warrants investor attention.
What This Means for Investors
Viking Therapeutics remains a classic example of a clinical-stage biotech where traditional earnings metrics fail to capture the investment narrative. The market capitalization of $3.82 billion and elevated price-to-book ratio suggest investors are betting on future drug approvals and pipeline success rather than current financial performance. The company’s GF Score™ of 34 underscores significant operational and profitability challenges, though its strong financial position and positive momentum provide some support.
Investor interest is further nuanced by mixed guru ownership trends and insider selling activity, signaling a cautious stance among sophisticated market participants. Given these dynamics, valuation should be approached with an understanding that VKTX is priced for growth potential rather than earnings, and the absence of reliable GF Valueâ„¢ data reflects this uncertainty.
For a deeper dive into Viking Therapeutics’ financials and market positioning, visit the VKTX stock page and consider screening for other biotech opportunities via the GuruFocus Stock Screener.
Frequently Asked Questions
What is VKTX's GF Scoreâ„¢?
VKTX’s GF Score™ is 34 out of 100, indicating weak overall financial health with particularly poor profitability but relatively strong financial strength and momentum.
How is VKTX valued?
Traditional valuation metrics like P/E are not meaningful due to VKTX’s ongoing losses. The stock trades at a high price-to-book ratio of 7.6, reflecting market expectations for future growth from its drug pipeline.
What is VKTX's P/E ratio compared to historical?
VKTX does not have a meaningful P/E ratio because it remains unprofitable, with a trailing EPS of -$4.14. Investors focus more on pipeline progress and cash position than earnings multiples.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
